FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308183799> ?p ?o ?g. }

• W4308183799 endingPage "109" @default.
• W4308183799 startingPage "95" @default.
• W4308183799 abstract "Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD-1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The pharmacokinetic (PK) profile of tislelizumab was analyzed with population PK modeling using 14,473 observed serum concentration data points from 2596 cancer patients who received intravenous (i.v.) tislelizumab at 0.5-10 mg/kg every 2 weeks or every 3 weeks (q3w), or a 200 mg i.v. flat dose q3w in 12 clinical studies. Tislelizumab exhibited linear PK across the dose range tested. Baseline body weight, albumin, tumor size, tumor type, and presence of antidrug antibodies were identified as significant covariates on central clearance, whereas baseline body weight, sex, and age significantly affected central volume of distribution. Sensitivity analysis showed that these covariates did not have clinically relevant effects on tislelizumab PK. Other covariates evaluated, including race (Asian vs. White), lactate dehydrogenase, estimated glomerular filtration rate, renal function categories, hepatic function measures and categories, Eastern Cooperative Oncology Group performance status, therapy (monotherapy vs. combination therapy), and line of therapy did not show a statistically significant impact on tislelizumab PK. These results support the use of tislelizumab 200 mg i.v. q3w without dose adjustment in a variety of patient subpopulations." @default.
• W4308183799 created "2022-11-09" @default.
• W4308183799 creator A5010226597 @default.
• W4308183799 creator A5017102600 @default.
• W4308183799 creator A5029898448 @default.
• W4308183799 creator A5030167007 @default.
• W4308183799 creator A5043786963 @default.
• W4308183799 creator A5058539150 @default.
• W4308183799 creator A5062749373 @default.
• W4308183799 creator A5067534714 @default.
• W4308183799 creator A5071468873 @default.
• W4308183799 creator A5077376806 @default.
• W4308183799 creator A5078590150 @default.
• W4308183799 date "2022-11-23" @default.
• W4308183799 modified "2023-09-26" @default.
• W4308183799 title "Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors" @default.
• W4308183799 cites W1950618346 @default.
• W4308183799 cites W1973097930 @default.
• W4308183799 cites W2005475183 @default.
• W4308183799 cites W2042553471 @default.
• W4308183799 cites W2065039877 @default.
• W4308183799 cites W2067933166 @default.
• W4308183799 cites W2567068937 @default.
• W4308183799 cites W2620733650 @default.
• W4308183799 cites W2790574591 @default.
• W4308183799 cites W2799565954 @default.
• W4308183799 cites W2900068522 @default.
• W4308183799 cites W2915355467 @default.
• W4308183799 cites W2919428266 @default.
• W4308183799 cites W2955110013 @default.
• W4308183799 cites W2978526561 @default.
• W4308183799 cites W2994547851 @default.
• W4308183799 cites W2999805537 @default.
• W4308183799 cites W3034803562 @default.
• W4308183799 cites W3036157555 @default.
• W4308183799 cites W3128021853 @default.
• W4308183799 cites W3153302452 @default.
• W4308183799 cites W3158704737 @default.
• W4308183799 cites W4308183799 @default.
• W4308183799 doi "https://doi.org/10.1002/psp4.12880" @default.
• W4308183799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36330700" @default.
• W4308183799 hasPublicationYear "2022" @default.
• W4308183799 type Work @default.
• W4308183799 citedByCount "2" @default.
• W4308183799 countsByYear W43081837992022 @default.
• W4308183799 countsByYear W43081837992023 @default.
• W4308183799 crossrefType "journal-article" @default.
• W4308183799 hasAuthorship W4308183799A5010226597 @default.
• W4308183799 hasAuthorship W4308183799A5017102600 @default.
• W4308183799 hasAuthorship W4308183799A5029898448 @default.
• W4308183799 hasAuthorship W4308183799A5030167007 @default.
• W4308183799 hasAuthorship W4308183799A5043786963 @default.
• W4308183799 hasAuthorship W4308183799A5058539150 @default.
• W4308183799 hasAuthorship W4308183799A5062749373 @default.
• W4308183799 hasAuthorship W4308183799A5067534714 @default.
• W4308183799 hasAuthorship W4308183799A5071468873 @default.
• W4308183799 hasAuthorship W4308183799A5077376806 @default.
• W4308183799 hasAuthorship W4308183799A5078590150 @default.
• W4308183799 hasBestOaLocation W43081837991 @default.
• W4308183799 hasConcept C112705442 @default.
• W4308183799 hasConcept C126322002 @default.
• W4308183799 hasConcept C126894567 @default.
• W4308183799 hasConcept C139254425 @default.
• W4308183799 hasConcept C143998085 @default.
• W4308183799 hasConcept C159641895 @default.
• W4308183799 hasConcept C159654299 @default.
• W4308183799 hasConcept C181199279 @default.
• W4308183799 hasConcept C185592680 @default.
• W4308183799 hasConcept C203014093 @default.
• W4308183799 hasConcept C2777318727 @default.
• W4308183799 hasConcept C2908647359 @default.
• W4308183799 hasConcept C542903549 @default.
• W4308183799 hasConcept C55493867 @default.
• W4308183799 hasConcept C71924100 @default.
• W4308183799 hasConcept C98274493 @default.
• W4308183799 hasConcept C99454951 @default.
• W4308183799 hasConceptScore W4308183799C112705442 @default.
• W4308183799 hasConceptScore W4308183799C126322002 @default.
• W4308183799 hasConceptScore W4308183799C126894567 @default.
• W4308183799 hasConceptScore W4308183799C139254425 @default.
• W4308183799 hasConceptScore W4308183799C143998085 @default.
• W4308183799 hasConceptScore W4308183799C159641895 @default.
• W4308183799 hasConceptScore W4308183799C159654299 @default.
• W4308183799 hasConceptScore W4308183799C181199279 @default.
• W4308183799 hasConceptScore W4308183799C185592680 @default.
• W4308183799 hasConceptScore W4308183799C203014093 @default.
• W4308183799 hasConceptScore W4308183799C2777318727 @default.
• W4308183799 hasConceptScore W4308183799C2908647359 @default.
• W4308183799 hasConceptScore W4308183799C542903549 @default.
• W4308183799 hasConceptScore W4308183799C55493867 @default.
• W4308183799 hasConceptScore W4308183799C71924100 @default.
• W4308183799 hasConceptScore W4308183799C98274493 @default.
• W4308183799 hasConceptScore W4308183799C99454951 @default.
• W4308183799 hasIssue "1" @default.
• W4308183799 hasLocation W43081837991 @default.
• W4308183799 hasLocation W43081837992 @default.
• W4308183799 hasLocation W43081837993 @default.
• W4308183799 hasOpenAccess W4308183799 @default.

• next